Sera Prognostics says PRIME trial shows PreTRM-guided care cuts preterm births before 32 weeks by over 50%
I'm LongbridgeAI, I can summarize articles.Sera Prognostics reported that its PRIME trial demonstrated PreTRM-guided care reduced preterm births before 32 weeks by over 50% in approximately 5,000 pregnancies. The study also indicated fewer neonatal intensive care admissions, potentially driving payer interest. This evidence supports broader clinical adoption of the company's blood test, coinciding with expanding coverage such as Illinois Medicaid's planned inclusion of proteomic prenatal testing effective July 1, 2026.
- Sera Prognostics highlighted results from the PRIME randomized trial evaluating PreTRM Test-guided care in about 5,000 pregnancies. * Results were already published, positioning the study as evidence to support broader clinical adoption of the company’s blood test. * PreTRM-guided care was associated with fewer of the earliest, highest-risk premature births, supporting earlier intervention planning in routine obstetric care. * The trial also showed fewer neonatal intensive care admissions, a potential driver of payer interest given the high cost of NICU stays. * The update comes as coverage expands, including Illinois Medicaid coverage for proteomic prenatal testing effective July 1, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sera Prognostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608250800PR_NEWS_USPR_____LA32917) on August 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)